1. Home
  2. TRVI vs SEG Comparison

TRVI vs SEG Comparison

Compare TRVI & SEG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TRVI
  • SEG
  • Stock Information
  • Founded
  • TRVI 2011
  • SEG 2024
  • Country
  • TRVI United States
  • SEG United States
  • Employees
  • TRVI N/A
  • SEG N/A
  • Industry
  • TRVI Biotechnology: Pharmaceutical Preparations
  • SEG
  • Sector
  • TRVI Health Care
  • SEG
  • Exchange
  • TRVI Nasdaq
  • SEG NYSE
  • Market Cap
  • TRVI 341.4M
  • SEG 343.2M
  • IPO Year
  • TRVI 2019
  • SEG N/A
  • Fundamental
  • Price
  • TRVI $3.76
  • SEG $26.50
  • Analyst Decision
  • TRVI Strong Buy
  • SEG
  • Analyst Count
  • TRVI 8
  • SEG 0
  • Target Price
  • TRVI $9.31
  • SEG N/A
  • AVG Volume (30 Days)
  • TRVI 659.4K
  • SEG 78.8K
  • Earning Date
  • TRVI 11-06-2024
  • SEG 02-05-2025
  • Dividend Yield
  • TRVI N/A
  • SEG N/A
  • EPS Growth
  • TRVI N/A
  • SEG N/A
  • EPS
  • TRVI N/A
  • SEG N/A
  • Revenue
  • TRVI N/A
  • SEG $111,487,000.00
  • Revenue This Year
  • TRVI N/A
  • SEG N/A
  • Revenue Next Year
  • TRVI N/A
  • SEG N/A
  • P/E Ratio
  • TRVI N/A
  • SEG N/A
  • Revenue Growth
  • TRVI N/A
  • SEG 36.09
  • 52 Week Low
  • TRVI $1.27
  • SEG $22.51
  • 52 Week High
  • TRVI $4.68
  • SEG $36.50
  • Technical
  • Relative Strength Index (RSI)
  • TRVI 48.03
  • SEG N/A
  • Support Level
  • TRVI $3.63
  • SEG N/A
  • Resistance Level
  • TRVI $4.06
  • SEG N/A
  • Average True Range (ATR)
  • TRVI 0.30
  • SEG 0.00
  • MACD
  • TRVI -0.09
  • SEG 0.00
  • Stochastic Oscillator
  • TRVI 12.21
  • SEG 0.00

About TRVI Trevi Therapeutics Inc.

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.

About SEG SEAPORT ENTERTAINMENT GROUP INC

Seaport Entertainment Group Inc own, operate and develop a unique collection of assets positioned at the intersection of entertainment and real estate. Its objective is to integrate one-of-a-kind real estate assets with a variety of restaurant, retail and leisure offerings to form vibrant mixed-use destinations where customers can work, play and socialize in one cohesive setting. The company has three operating segments: (1) Landlord Operations; (2) Hospitality; and (3) Sponsorships, Events, and Entertainment. Key revenue is generated from Landlord Operations which consists of the company's rental operations.

Share on Social Networks: